Friday, 02 December 2022

Alkem Labs launches Alfluenza for COVID-19 treatment

07 August 2020 | News

For the management of mild to moderate cases of COVID-19

Image credit- shutterstock.com

Image credit- shutterstock.com

The cases of COVID-19 is increasing significantly globally and India too is affected with around 50,000 new cases being added on a daily basis.

In this backdrop, Mumbai based Alkem Laboratories Ltd. has launched Favipiravir under the brand name “Alfluenza” in India for the management of mild to moderate cases of COVID-19.

Favipiravir is approved by DCGI (Drug Controller General of India) for restricted emergency use in India.

Restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account